Protalix BioTherapeutics
PLX
PLX
62 hedge funds and large institutions have $11.9M invested in Protalix BioTherapeutics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
34% less capital invested
Capital invested by funds: $18M → $11.9M (-$6.08M)
Holders
62
Holding in Top 10
–
Calls
$62K
Puts
$17K
Top Buyers
| 1 | +$200K | |
| 2 | +$198K | |
| 3 | +$51.5K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$47.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$37.2K |
Top Sellers
| 1 | -$411K | |
| 2 | -$185K | |
| 3 | -$169K | |
| 4 |
OGF
Orin Green Financial
San Diego,
California
|
-$142K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$126K |